Qhslab, INC 10-Q quarterly reports

QHSLab, Inc. filed its Q2 2026 10-Q, showing increased revenues driven by its Integrated Service Program, but continued operating losses and a going concern warning.

QHSLab, Inc. reported Q1 2026 results with a 13% increase in revenue driven by its Integrated Service Program, despite a net loss.

QHSLab, Inc. reported a net loss of $99,156 for the nine months ended September 30, 2025, despite a 31.9% revenue increase, as it grapples with significant debt defaults and going concern doubts.

QHSLab, Inc. reported increased revenue for Q2 2025 and the first half of 2025, driven by Integrated Service Program and new clinical study revenue, but faced a significantly higher net loss due to increased operating and default interest expenses, raising substantial doubt about its going concern ability.

QHSLab, Inc. reports increased revenue for the quarter ended March 31, 2025, but continues to experience net losses and going concern uncertainties.

QHSLab, Inc. saw increased revenue and gross profit in the third quarter of 2024, driven by growth in integrated service programs and allergy diagnostic kit sales, but faces ongoing concerns about its ability to continue as a going concern due to significant debt and defaults.

QHSLab, Inc. saw a revenue increase in the second quarter of 2024, primarily driven by a significant rise in its Integrated Service Program revenue.

QHSLab, Inc. saw a revenue increase in Q1 2024 compared to Q1 2023, driven by growth in integrated service program revenue and allergy diagnostic kit sales, but continues to face financial challenges.